Category: biotech

.AbbVie has actually gone back to the source of its own antipsychotic powerhouse Vraylar in search of one more runaway success, paying for $25 thousand

.On the same day that some Parkinson’s illness medications are being actually called into question, AbbVie has announced that its late-stage monotherapy prospect has dramatically

.AstraZeneca has used expert system to devise a distinct biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), planning to differentiate the antibody-drug conjugate (ADC)

.Monopar Rehabs is actually recuperating a medication coming from the scrap heap of AstraZeneca’s uncommon health condition pipeline. It has licensed ALXN-1840, an applicant for